Le Lézard
Classified in: Health
Subject: PLW

Natural Alternatives International, Inc. Announces Allowance of New U.S. Instant Release Beta-Alanine Patent Application


CARLSBAD, Calif., Jan. 17, 2018 /PRNewswire/ -- Natural Alternatives International, Inc. ("NAI") (NASDAQ: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for NAI instant release beta-alanine patent application entitled "Methods And Compositions For Increasing The Anaerobic Working Capacity In Tissues."  The newly allowed application becomes part of NAI's global patent estate covering its CarnoSyn® instant release beta-alanine product.

Mark A. LeDoux, NAI's CEO and Chairman of the Board, said that "this patent provides athletes with important guidance related to increasing muscle carnosine levels and achieving a maintenance level from which the athlete can build as desired over time with varying amounts of beta-alanine supplementation."  As another important piece to NAI's global strategy for providing performance increases well beyond those achievable through normal diets, this patent "will insure that athletes have the appropriate information and abilities to adequately reach their competitive goals," said Mr. LeDoux.  NAI's allowed claims are directed to methods of delaying muscle fatigue through supplementation with instant release beta-alanine in times and amounts to increase muscle carnosine levels beyond that obtainable through diet alone.  The claimed methods allow for a loading phase and a maintenance phase of supplementation, and allows for further loading after achieving and maintaining a desired level of muscle carnosine. 

NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI's comprehensive partnership approach offers a wide range of innovative nutritional products and services to NAI's clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see its website at http://www.nai-online.com.

This press release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, the outcome of pending litigation, the continued validity of our patents, and our ability to successfully develop, license and enforce our intellectual property rights. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

CONTACT: Kenneth Wolf, President, Natural Alternatives International, Inc., at 760-736-7700 or [email protected].

WEBSITE:  http://www.nai-online.com and http://www.carnosyn.com

SOURCE Natural Alternatives International, Inc.


These press releases may also interest you

at 05:15
The "Flow Cytometry Markets. Forecasts by Technology, Product and Application. With Executive and Consultant Guides. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. The technology is moving faster than the market. Find the...

at 05:00
The "Immunoassay Markets. Strategies and Trends. Forecasts by Application, Technology, Product, User and by Country. With Executive Guides, Customized Forecasting and Analysis. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering....

at 05:00
Medical equipment manufacturing company Aohua Endoscopy clinched the Endoscopy Product Innovation Award at the recently held Healthcare Asia Medtech Awards 2024 for its development of the Aohua 4K AQ-300 video endoscopy system, which offers an...

at 03:52
The progressive decrease in hearing in elderly people can represent a major problem for their quality of life: it has in fact been demonstrated that critical issues such as these, in addition to being a problem as such, can...

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...



News published on and distributed by: